Company intelligence / Profile preview
Montara Therapeutics
San Francisco, California, USAmontaratx.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Preclinical
01
Overview
Montara Therapeutics is a precision-medicine neuroscience biotech developing safer, more efficacious therapies for neurological diseases using its proprietary BrainOnly™ platform. The company has rapidly advanced its lead rare epilepsy candidate toward IND-enabling studies with in vivo proof-of-concept achieved within one year. A second neurodegeneration-focused asset has reached development candidate status, with a third preclinical CNS pipeline asset also underway. The company recently closed an oversubscribed $20M seed expansion round to accelerate these programs.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (noted as inhibitors or activators)Brain-targeted therapeutics via proprietary platform
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Montara Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Montara Therapeutics.